Irbesartan/Hydrochlorothiazid Micro Labs

Irbesartan, the active ingredient in Irbesartan/Hydrochlorothiazid Micro Labs, is an angiotensin II receptor blocker presented as a combination tablet for oral use. It treats hypertension, often in combination with a diuretic, and is used in adults. GNH USA supplies Irbesartan/Hydrochlorothiazid Micro Labs as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Irbesartan/Hydrochlorothiazid Micro Labs is manufactured for the EU market and distributed by GNH USA under strict quality standards.

Irbesartan/Hydrochlorothiazid is indicated for hypertension management, acting on the renin‑angiotensin‑aldosterone system to lower blood pressure. - Hypertension: helps achieve target blood pressure when lifestyle measures are insufficient. - Heart failure with reduced ejection fraction: used as part of combination therapy to reduce morbidity. - Diabetic nephropathy: slows progression of kidney damage in patients with type 2 diabetes. - Post‑myocardial infarction: assists in blood‑pressure control to lower risk of recurrent events. - Chronic kidney disease: aids in blood‑pressure control to protect renal function.

Common Side Effects: - Dizziness: may occur especially after the first doses. - Headache: mild to moderate intensity. - Fatigue: general feeling of tiredness. - Increased urination: due to the diuretic component. - Electrolyte imbalance: mild changes in potassium or sodium levels. - Cough: occasional dry throat irritation. Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure causing fainting. - Acute kidney injury: sudden decline in renal function. - Hyperkalemia: dangerously high potassium levels. - Angio‑edema: swelling of face, lips, or airway. - Liver injury: elevated transaminases or jaundice. - Blood dyscrasias: rare blood cell abnormalities.

When prescribing Irbesartan/Hydrochlorothiazid, clinicians should consider patient‑specific factors and monitor relevant parameters. - Renal function: assess baseline creatinine and eGFR before initiation. - Electrolytes: monitor potassium and sodium levels regularly. - Blood pressure: check for excessive hypotension after dose changes. - Pregnancy: avoid use in the second and third trimesters due to fetal risk. - Drug interactions: review concomitant medications for additive hypotensive effects. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Irbesartan/Hydrochlorothiazid may interact with several drug classes, requiring careful management. Major Interactions (Avoid): - Potassium‑sparing diuretics or supplements: risk of hyper‑kalemia. - ACE inhibitors or other ARBs: additive renal impairment and hypotension. - NSAIDs: may blunt antihypertensive effect and affect renal function. Moderate Interactions (Monitor Closely): - Lithium: increased lithium levels and toxicity risk. - Antidiabetic agents: enhanced hypoglycaemic effect. - Beta‑blockers: may potentiate blood‑pressure lowering. - Cyclosporine or tacrolimus: increased risk of nephrotoxicity. - Digoxin: altered serum concentrations.